Darwin Global Management, Ltd.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Darwin Global Management, Ltd. reported 6 stock positions worth $1.1 billion. Its top holding was Insmed (INSM) at 84.8% of the portfolio, followed by Jazz Pharmaceuticals (JAZZ, 5.7%) and Verona Pharma (VRNA, 3.6%). Compared with Q3 2024, it opened 3 new positions, sold out of 2, added to 2 and reduced 1. The biggest buy was Insmed (INSM, shares +23%) and the biggest sale an exit from Vaxcyte (PCVX).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001839209
- Portfolio Value
- $1.1B (Q4 2024)
- SEC Filing
- 0001892688-25-000094 ↗ filed Feb 14, 2025
Holdings Value
Holdings 6 stocks · $1.1B
| INSM Insmed Inc. | 84.75% | 12,960,538 | $894.8M | Add +23.5% |
| JAZZ Jazz Pharmaceuticals PLC | 5.65% | 484,515 | $59.7M | New |
| VRNA Verona Pharma Ltd. | 3.56% | 810,449 | $37.6M | New |
| GERN Geron Corp. | 3.21% | 9,569,835 | $33.9M | Reduce -56.6% |
| KROS Keros Therapeutics Inc. | 2.53% | 1,687,135 | $26.7M | Add +10.7% |
| NRIX Nurix Therapeutics Inc. | 0.29% | 163,681 | $3.1M | New |
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $3.8B | RVMD, INSM, BLTE, ABVX, ROIV |
| Q1 2026 | 6 | $3.8B | INSM, BLTE, ABVX, RVMD, ROIV |
| Q4 2025 | 6 | $4.9B | INSM, BLTE, ABVX, CDTX, WVE |
| Q3 2025 | 5 | $3.6B | INSM, UTHR, ABVX, CDTX, QURE |
| Q2 2025 | 5 | $2.4B | INSM, VRNA, CDTX, MRUS, ALLO |
| Q1 2025 | 3 | $1.5B | INSM, VRNA, ALLO |
| Q4 2024 | 6 | $1.1B | INSM, JAZZ, VRNA, GERN, KROS |
| Q3 2024 | 5 | $1.2B | INSM, PCVX, GERN, KROS, SMMT |
| Q2 2024 | 9 | $859.5M | CYTK, INSM, PCVX, GERN, KROS |
| Q1 2024 | 12 | $751.2M | PCVX, NUVL, KROS, BHVN, ALPN |